Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States
Titel:
Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States
Auteur:
Chiddarwar, Tanvi V. Jalal, Hawre Alarid-Escudero, Fernando Garibay, David Kumar, Praveen Chowdhury, Krishna Roy Jacobs, Bruce L. Mathew, Paul Wong, John B. Kuntz, Karen M.